January 19, 2022
SPIE Photonics West and BiOS Expo, Jan 22 – 27 in San Francisco
If you are interested in the interface between cancer immunotherapy innovation and photonics, then catch up with Tomas Hode, PhD,...
Read More
September 14, 2021
USPTO Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001
Immunophotonics is pleased to announce that the United States Patent and Trademark has issued U.S. Patent No. 11111316, which covers...
Read More
September 7, 2021
Immunophotonics Switzerland (IPS Biopharma) Invited to Present at Swiss Biotech Day
Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day in the Emerging Company session hosted by BB...
Read More
September 1, 2021
Immunophotonics Publishes Follow-up Feature in Nature Biopharma Dealmakers
Immunophotonics is excited to be featured in the September 2021 oncology issue of Nature Biopharma Dealmakers. Read what Dr. Markus...
Read More
March 1, 2021
Immunophotonics Featured in Nature Biopharma Dealmakers
Immunophotonics has been featured in the March oncology issue of Nature Biopharma Dealmakers (www.nature.com/articles/d43747-021-00020-2 ). Nature selects only a handful...
Read More
February 25, 2021
Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies
A paper recently published in Cells has described how Immunophotonics' immune-stimulating drug IP-001 was shown to be effective against metastatic...
Read More
November 10, 2020
Immunophotonics Announces First Patient Treated in Swiss Clinical Trial
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the...
Read More
October 15, 2020
Potential COVID-19 Applications of Immunophotonics’ Leading Drug Candidate, IP-001, Being Researched at the University of Oklahoma
OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen...
Read More
October 5, 2020
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a...
Read More
June 21, 2019
Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled "Intratumoral Injection of IP-001 Following Thermal Ablation in...
Read More